慢性丙型肝炎治疗:优化与发展

被引：12

作者：

魏来

机构：

[1] 北京大学人民医院

来源：

传染病信息 | 2009年 / 22卷 / 04期

关键词：

丙型肝炎; 抗病毒治疗; 干扰素α; 利巴韦林; 肝硬化; HIV感染; 肝移植;

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

摘要：

聚乙二醇干扰素α联合利巴韦林已成为慢性丙型肝炎的标准治疗方法,但仍有部分患者未能获得持续病毒学应答(sustained virologic response,SVR)。根据治疗基线时的病毒载量、基因型以及治疗过程中的应答可以优化抗病毒治疗的方案。对于标准治疗或延长疗程仍不能获得SVR者,通过特异性靶向抗丙型肝炎病毒治疗可以提高应答。对于其他的难治性丙型肝炎患者,包括合并HIV感染者、肝硬化患者以及器官移植患者,抗病毒治疗也取得了进展。

引用

页码：196 / 199

页数：4

共 9 条

[1]

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy[J] . Gastroenterology . 2009 (5)

[2]

12 DETECTION OF RESISTANT VARIANTS IN THE HEPATITIS C VIRUS NS3 PROTEASE GENE BY CLONAL SEQUENCING AT LONG-TERM FOLLOW-UP IN PATIENTS TREATED WITH BOCEPREVIR[J] . S. Susser,N. Forestier,M.W. Welker,J. Vermehren,U. Karey,S. Zeuzem,C. Sarrazin.Journal of Hepatology . 2009

[3]

4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON? (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C[J] . P. Kwo,E. Lawitz,J. McCone,E. Schiff,J. Vierling,D. Pound,M. Davis,J. Galati,S. Gordon,N. Ravendhran,L. Rossaro,F. Anderson,I. Jacobson,R. Rubin,K. Koury,C. Brass,E. Chaudhri,J. Albrecht.Journal of Hepatology . 2009

[4]

Diagnosis, management, and treatment of hepatitis C: An update[J] . Marc G. Ghany,Doris B. Strader,David L. Thomas,Leonard B. Seeff.Hepatology . 2009 (4)

[5]

Hepatitis C therapy before and after liver transplantation[J] . Norah A. Terrault.Liver Transpl . 2008 (S2)

[6]

4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C[J] . J.G. Mchutchison,G.T. Everson,S.C. Gordon,I. Jacobson,R. Kauffman,L. McNair,A. Muir.Journal of Hepatology . 2008

[7]

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin[J] . Thomas Berg,Michael von Wagner,Samer Nasser,Christoph Sarrazin,Tobias Heintges,Tilman Gerlach,Peter Buggisch,Tobias Goeser,Jens Rasenack,Gerd R. Pape,Wolfgang E. Schmidt,Birgit Kallinowski,Hartwig Klinker,Ulrich Spengler,Peter Martus,Ulrich Alshuth,Stefan Zeuzem.Gastroenterology . 2006 (4)

[8] High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].

Bressler, BL ;

Guindi, M ;

Tomlinson, G ;

Heathcote, J .

HEPATOLOGY, 2003, 38 (03) :639-644

[9] Treatment of viral hepatitis - 2001 [J].

Gordon, SC .

ANNALS OF MEDICINE, 2001, 33 (06) :385-390

← 1 →